Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1633 1635 1656 1658
This examiner grants 0% of resolved cases
Corey Lane Bretz is an examiner in Tech Center 1600 and Art Unit 1600. The examiner has 3 resolved cases and an allowance rate of 0.0 percent. The interview lift is also 0.0 percent. These figures indicate that none of the 3 resolved cases have resulted in an allowance, regardless of whether an interview was conducted.
The median days to allowance for cases in this docket is 954. Practitioners should consider the 0.0 percent allowance rate as an indicator of a challenging prosecution environment in Art Unit 1600. The 0.0 percent lift suggests that current interview strategies have not yet impacted outcomes.
The 3 resolved cases provide a limited basis for understanding the 954 day timeline. The allowance rate reflects the examiner's historical approach to applications. Applicants can use the data to plan their strategy in Tech Center 1600. This profile provides a data-grounded view of the prosecution environment for this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18338150 | COMPOSITIONS AND METHODS FOR MODIFYING RNA | Final Rejection | The Regents of the University of California |
| 18901470 | Methods for Rule-based Genome Design | Non-Final OA | President and Fellows of Harvard College |
| 17719431 | Methods for Rule-based Genome Design | Non-Final OA | President and Fellows of Harvard College |
| 18283262 | PRODUCTION OF CIRCULAR POLYRIBONUCLEOTIDES IN A PROKARYOTIC SYSTEM | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS VII, LLC |
| 18483090 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USING HLA-F | Non-Final OA | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18291018 | GENERATION OF LARGE PROTEINS BY CO-DELIVERY OF MULTIPLE VECTORS | Non-Final OA | UNIVERSITY OF WASHINGTON |
| 17773572 | ENGINEERED CELLS FOR CONTROLLED PRODUCTION | Non-Final OA | William Marsh Rice University |
| 18571924 | THERAPEUTIC NUCLEIC ACIDS AND METHODS OF USE THEREOF | Non-Final OA | Cedars-Sinai Medical Center |
| 18350077 | METHODS AND FORMULATIONS FOR GENE THERAPY, AND FOR COMBINING GENE THERAPY WITH DITPA TREATMENT, OF ALLAN-HERNDON-DUDLEY SYNDROME | Final Rejection | Cedars-Sinai Medical Center |
| 18336493 | SYSTEMS AND METHODS FOR TREATING CONDITIONS AND DISEASES USING ALTERNATING ELECTRIC FIELDS AND CRISPR-CAS SYSTEM | Non-Final OA | Novocure GmbH |
| 17997004 | COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ANGELMAN SYNDROME | Final Rejection | The Trustees of the University of Pennsylvania |
| 18193033 | FLUOROARABINO NUCLEIC ACID (FANA) APTAMERS THAT BIND SARS-2 RECEPTOR BINDING DOMAIN AND BLOCK BINDING TO THE ACE2 CELLULAR RECEPTOR | Non-Final OA | University of Maryland, College Park |
| 18623281 | RENAL INJURY BIOMARKERS AS BIOMARKERS FOR ACUTE HEPATIC PORPHYRIA (AHP) | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17921338 | TARGETED GENOMIC INTEGRATION TO RESTORE NEUROFIBROMIN CODING SEQUENCE IN NEUROFIBROMATOSIS TYPE 1 (NF1) | Final Rejection | Duke University |
| 18687385 | Modulation of TJPI Expression to Treat Liver Diseases | Non-Final OA | AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH |
| 18151093 | RECOMBINANT ADENOVIRUS GENOME HAVING A SYNTHETIC TRANSCRIPTIONAL UNIT AND TWO STEP TRANSCRIPTIONAL REGULATION AND AMPLIFICATION | Non-Final OA | Salk Institute for Biological Studies |
| 17741311 | COMPOSITIONS AND METHODS FOR HIGH-EFFICIENCY RECOMBINATION OF RNA MOLECULES | Non-Final OA | Salk Institute for Biological Studies |
| 18573657 | NON-NATURAL 5'-UNTRANSLATED REGION AND 3'-UNTRANSLATED REGION AND USE THEREOF | Non-Final OA | HANMI PHARM. CO., LTD. |
| 18687892 | IVT RNA MANUFACTURING PROCESS | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18626784 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | Non-Final OA | Genzyme Corporation |
| 18296283 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | Final Rejection | Genzyme Corporation |
| 18703672 | BAG3 METHODS AND USES FOR TREATMENT OF INFLAMMATION | Non-Final OA | LOYOLA UNIVERSITY OF CHICAGO |
| 17913728 | FORSKOLIN-INDUCIBLE PROMOTERS AND HYPOXIA-INDUCIBLE PROMOTERS | Final Rejection | ASKLEPIOS BIOPHARMACEUTICAL, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy